# ARC-20 (NCT05536141)

> A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05536141
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Arcus Biosciences, Inc.
- Conditions: Clear Cell Renal Cell Carcinoma; Solid Tumors
- Interventions: casdatifan; Cabozantinib; Zimberelimab; Ipilimumab
- Enrollment: 362
- Primary outcome: Number of participants with dose limiting toxicities (DLTs)
- Primary outcome: Number of participants with adverse events (AEs)

## Commentary we found

- X threads: 25
- YouTube: 12
- Podcasts: 11
- X videos: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=arc-20-nct05536141

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05536141", "email": "<work email>"}; the inbox owner confirms by the emailed link.